The T877A-AR mutations, which is also present in prostate cancer cell line LNCaP, has been reported by various individuals to occur in 25 to 33% of androgen-independent or castrate-resistant tumors [11], [14], [15], [16]. Here, AR is linked to prostate carcinoma.